Evaluation of Efficacity & Safety of Deep Brain Stimulation (DBS) in

Status Completed

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of deep brain stimulation (DBS) in chronic and treatment-resistant CH. Inclusion criteria are: patients with chronic CH (>3years), with daily attack and non response to adequate treatment. Electrodes are implanted stereotactically in the postero-inferior hypothalamus. In this crossover, randomized, placebo-controlled double-blinded study, the efficacy of DBS is evaluated using comparison of two one-month sequences: one with stimulation "on" and the other with stimulation "off" (placebo sequence). Efficacy is defined as ≥50% decrease of weekly frequency of CH attacks. After the randomized period, long-term efficacy and safety are evaluated after one year of stimulation in open conditions.

Clinical Trial Description

Over the past 7 years, deep brain stimulation (DBS) has been used in various centres to treat patients with intractable chronic cluster headache (CH). Results in these non-controlled studies were encouraging but need to be confirmed in controlled conditions. The aim of this study is to evaluate the efficacy and safety of DBS in chronic and treatment-resistant CH, in randomized placebo-controlled conditions.

Inclusion criteria are: patients with chronic CH (>3years), with daily attack and non response to adequate treatment (verapamil up 960 mg/d, lithium with plasmatic level 0.6-1 mEq/ ml, and association of both drugs). After induction of local anaesthesia, electrodes are implanted stereotactically in the postero-inferior hypothalamus according to the previously described coordinates, and connected to a sub-cutaneous generator. In this crossover, randomized, placebo-controlled double-blinded study, the efficacy of DBS is evaluated using comparison of two one-month sequences: one with stimulation "on" and the other with stimulation "off" (considered as the placebo sequence). Primary efficacy is defined as ≥50% decrease of weekly frequency of CH attacks, compared to a prospective run-in pre-implantation period. Safety and tolerability are clinically and biologically assessed. After the randomized period, long-term efficacy and safety are evaluated after one year of stimulation in open conditions. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00662935
Study type	Interventional
Source	Centre Hospitalier Universitaire de Nice
Contact
Status	Completed
Phase	N/A
Start date	May 2005
Completion date	March 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05264714` - Cluster Headache Treatment With Rimegepant	Phase 2
Completed	`NCT01677026` - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated	`NCT00203190` - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache	Phase 4
Recruiting	`NCT04570475` - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache	Phase 3
Completed	`NCT04066023` - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches	Phase 2/Phase 3
Withdrawn	`NCT04353505` - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache	Phase 1
Completed	`NCT02019017` - Botox Injection in Treatment of Cluster Headache	Phase 1/Phase 2
Recruiting	`NCT05153876` - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting	`NCT05324748` - Repeated GON Injections in CCH	Phase 3
Completed	`NCT02782533` - DBS of the Third Ventricle for Cluster Headache and Obesity	N/A
Completed	`NCT04179266` - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache	Phase 1/Phase 2
Recruiting	`NCT04406259` - Atrioventricular Block and Cluster Headache (SEVA)	Phase 4
Recruiting	`NCT06206772` - Resting State Functional Connectivity in Cluster Headache
Recruiting	`NCT03944876` - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache	Phase 3
Not yet recruiting	`NCT05857098` - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting	`NCT02910323` - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated	`NCT00458770` - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks	N/A
Active, not recruiting	`NCT03511846` - Pain Biomarker Study	Phase 1
Completed	`NCT00184587` - Prophylactic Treatment of Episodic Cluster Headache	Phase 2
Not yet recruiting	`NCT06277063` - nVNS for the Prevention and Treatment of Primary Headache	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms